UGT3A1 Inhibitors
UGT3A1 inhibitors encompass a diverse array of chemical compounds that influence the activity of UGT3A1 in various ways. Some compounds operate by directly competing for the active site of the enzyme, thereby preventing the conjugation of substrates integral to the enzyme's function. Other inhibitors act indirectly, by modulating the availability of essential cofactors or substrates required for enzymatic activity. For instance, compounds that interfere with the metabolism of cofactors or sequester them through chelation can significantly reduce the glycosylation process in which UGT3A1 is involved. Additionally, the inhibition of glucose transporters by certain molecules can lead to a scarcity of UDP-glucose, a crucial substrate for UGT3A1, effectively diminishing its glycosylation capacity.
Furthermore, there are inhibitors that affect UGT3A1 activity by altering the expression levels or the regulatory pathways associated with the enzyme. These include molecules that modulate transcription factors, which are responsible for the regulation of detoxification enzymes, thereby influencing the expression of UGT3A1. Additionally, some compounds can influence the transport of glucuronides, which are the end products of UGT3A1 enzymatic activity, thereby indirectly affecting the enzyme's activity through feedback mechanisms. Other inhibitors interact with signaling pathways that can lead to changes in the expression or activity of UGT3A1. For example, inhibition of inflammatory pathways or modulation of liver-specific metabolic processes can downregulate the enzyme's expression. The presence of certain polyphenols might lower the expression levels of UGT3A1 by inhibiting nucleic acid synthesis, which is a broader metabolic effect but nonetheless impacts the enzyme's activity. Also, the modulation of phosphorylation events by kinase inhibitors can result in decreased enzyme activity, as phosphorylation is often crucial for the functionality of metabolic enzymes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $64.00 $255.00 | 13 | |
This compound inhibits the function of various glucose transporters, which could reduce the availability of UDP-glucose, a necessary substrate for UGT3A1 activity. Reduced substrate availability leads to decreased activity of UGT3A1. | ||||||
Kojic acid | 501-30-4 | sc-255228 sc-255228A | 5 g 25 g | $94.00 $176.00 | 1 | |
Kojic acid is a chelator of divalent cations. By chelating magnesium ions, it could impair the glycosylation process, as magnesium is a cofactor necessary for UGT3A1 enzymatic activity. | ||||||
(±)-Sulfinpyrazone | 57-96-5 | sc-202822 sc-202822A | 1 g 5 g | $42.00 $94.00 | 2 | |
As a competitive inhibitor of glucuronosyltransferase enzymes, this compound could inhibit UGT3A1 by competing for the active site, thus preventing the conjugation of substrates. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $28.00 $39.00 $100.00 $277.00 | 28 | |
Probenecid inhibits various anion transporters and uricosuric agents. It could inhibit UGT3A1 by interfering with the transport of glucuronides, which are products of UGT3A1's glucuronidating activity. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
By inhibiting cytochrome P450 enzymes, fluconazole can alter the metabolic balance in the liver, which could lead to a reduction in UGT3A1's activity due to substrate competition or altered cofactor availability. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $40.00 | 7 | |
This diterpenoid compound is known to inhibit NF-κB activation. Since NF-κB can regulate the expression of detoxification enzymes, andrographolide may downregulate UGT3A1 expression by inhibiting this transcription factor. | ||||||
Silymarin group, mixture of isomers | 65666-07-1 | sc-301806 | 50 g | $325.00 | ||
Silymarin is an antioxidant that modulates enzymes involved in detoxification. By altering the regulation of these enzymes, silymarin could lead to a decrease in UGT3A1 activity. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
This flavonoid inhibits a wide range of enzymes and has been shown to affect glucuronidation processes. It could inhibit UGT3A1 through direct interaction with the enzyme or by modulating related signaling pathways. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin can modulate various signaling pathways and may inhibit UGT3A1 either by direct enzyme interaction or by influencing related metabolic pathways. | ||||||
Piperine | 94-62-2 | sc-205809 sc-205809A | 5 g 25 g | $37.00 $146.00 | 3 | |
As an inhibitor of various enzymes and an enhancer of bioavailability, piperine could inhibit UGT3A1 activity by directly interacting with the enzyme or altering the hepatic metabolism that affects UGT3A1 function. | ||||||